+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Bispecific Antibody Therapeutics Contract Manufacturing Market Size, Share & Trends Analysis Report By Indication (Cancer, CNS Conditions), By Route of Administration, By End-use, By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 175 Pages
  • August 2023
  • Region: Global
  • Grand View Research
  • ID: 5876206
The global bispecific antibody therapeutics contract manufacturing market size is expected to reach USD 62.65 billion by 2030 and is projected to grow at a CAGR of 36.4% from 2023 to 2030. The bispecific antibodies (bsAB) represent a rapidly growing therapeutic approach with the emerging development of recombinant DNA technology and understanding of antibody engineering. These antibody therapeutics offer a range of therapeutic benefits to serve the unmet needs of patients. In addition, the therapeutic potential to treat cancer, diabetes, Alzheimer's, and ophthalmological diseases drive the market need. The abundant attention and investment in bispecific antibodies are the key factors for market growth.

Likewise, ongoing research activities in drug discovery, preclinical, and clinical stage studies, as well as numerous antibodies entering clinical development offer a promising future for patients suffering from various diseases that do not have many treatment options. For instance, according to WuXi Biologics, 100+ different bispecific formats are currently available, wherein approximately 160 bispecific antibodies are in clinical trials & 460 bispecific antibodies are in pre-clinical development. The rising number of clinical trials is expected to lead the way in antibody-based therapeutics. In addition, the rapid success of bispecific antibody therapeutics in cancer and non-cancer programs has boosted the demand for the market. With the growing burden of cancer, bispecific antibody therapeutics have gained success in the treatment of various cancer diseases.

For instance, according to Sino Biological Inc., more than 85% of bispecific antibodies in clinical trials are cancer therapeutics. Similarly, as of 2022, a total of six bsAbs have received approval by EMA and FDA in cancer immunotherapy including the initially approved bsAb, Catumaxomab. The COVID-19 pandemic has positively impacted the growth of the bispecific antibody therapeutics contract manufacturing industry. The increasing research and development activities and pre-clinical trials for bispecific antibodies have certainly shown the potential to neutralize SARS-CoV-2 and its variants. Besides, the high bispecific potency and overall characteristics of bsAbs make it an ideal choice for clinical trials further supporting for prevention and treatment of COVID-19. Furthermore, the key participants are engaged in strategies, such as bispecific antibody therapeutics approvals, partnerships, agreements, collaborations, and launches, to expand their global footprints and product portfolio.

For instance, in August 2022, the European Commission granted Janssen Pharmaceutical Companies of Johnson & Johnson company’s TECVAYLI (teclistamab) with conditional marketing authorization. TECVAYLI (teclistamab) is a monotherapy for the treatment of adult patients with relapsed & refractory multiple myeloma. In addition, in October 2022, the FDA granted accelerated approval to Tecvayli. Similarly, in June 2022, the European Commission granted Roche company’s CD20xCD3 T-cell binding bispecific antibody Lunsumio (mosunetuzumab) a conditional marketing authorization. It will be used for the treatment of follicular lymphoma, relapsed or refractory, in patients who have received prior two systemic therapies.

Bispecific Antibody Therapeutics Contract Manufacturing Market Report Highlights

  • Based on indication, the cancer segment held the largest revenue share of 55.7% in 2022. The immense demand for bispecific antibody therapeutics drives the segment. In addition, the market for antibody therapeutics has become an attractive choice to treat cancer, due to its safety and efficacy profile
  • Based on the route of administration, the intravenous segment held the largest share of 45.2% in 2022, owing to its advantages in recovery. These antibodies not only efficiently recruit the endogenous bone marrow stem cells, but also support the cell's target
  • In terms of end-use, the biopharmaceutical companies segment is anticipated to register the fastest CAGR of 37.1% from 2023 to 2030. This is due to the high burden of cancer, increasing demand for advanced antibody therapies, a growing number of clinical trials, rising R&D activities, and investments
  • North America held the largest revenue share of 69.7% in 2022. The presence of well-established market players, increasing burden of cancer & other diseases, growing research activities, rising number of clinical trials, and investments are driving the regional market growth

Table of Contents

Chapter 1. Methodology And Scope
1.1. Market Segmentation & Scope
1.1.1. Segment Definitions
1.1.2. Indication
1.1.3. Route of Administration
1.1.4. End Use
1.2. Regional Scope
1.3. Estimates And Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information Or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.9.2. Parent Market Analysis
1.10. List Of Secondary Sources
1.11. List Of Abbreviations
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Bispecific Antibody Therapeutics Contract Manufacturing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Ongoing Research Activities in Bispecific Antibody Therapeutics
3.2.1.2. Rapid success of bispecific antibody therapeutics in cancer and non-cancer programs
3.2.2. Market Restraint Analysis
3.2.2.1. Challenges associated with manufacturing of bispecific antibody therapeutics
3.3. Bispecific Antibody Therapeutics Contract Manufacturing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat Of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Bispecific Antibody Therapeutics Contract Manufacturing Market: Indication Estimates & Trend Analysis
4.1. Bispecific Antibody Therapeutics Contract Manufacturing Market, By Indication: Segment Dashboard
4.2. Bispecific Antibody Therapeutics Contract Manufacturing Market, By Indication: Movement Analysis
4.3. Bispecific Antibody Therapeutics Contract Manufacturing Market Estimates & Forecasts, By Indication, 2018 - 2030
4.3.1. Cancer
4.3.1.1. Cancer Bispecific Antibody Therapeutics Contract Manufacturing Market, 2018 to 2030 (USD Million)
4.3.2. Infectious Diseases
4.3.2.1. Infectious Diseases Bispecific Antibody Therapeutics Contract Manufacturing Market, 2018 to 2030 (USD Million)
4.3.3. Autoinflammatory and Autoimmune Diseases
4.3.3.1. Autoinflammatory and Autoimmune Diseases Bispecific Antibody Therapeutics Contract Manufacturing Market, 2018 to 2030 (USD Million)
4.3.4. CNS Conditions
4.3.4.1. CNS Conditions Bispecific Antibody Therapeutics Contract Manufacturing Market, 2018 to 2030 (USD Million)
4.3.5. Others
4.3.5.1. Others Bispecific Antibody Therapeutics Contract Manufacturing Market, 2018 to 2030 (USD Million)
Chapter 5. Bispecific Antibody Therapeutics Contract Manufacturing Market: Route of Administration Estimates & Trend Analysis
5.1. Bispecific Antibody Therapeutics Contract Manufacturing Market, By Route of Administration: Segment Dashboard
5.2. Bispecific Antibody Therapeutics Contract Manufacturing Market, By Route of Administration: Movement Analysis
5.3. Bispecific Antibody Therapeutics Contract Manufacturing Market Estimates & Forecasts, By Route of Administration, 2018 - 2030
5.3.1. Intravenous
5.3.1.1. Intravenous Bispecific Antibody Therapeutics Contract Manufacturing Market, 2018 to 2030 (USD Million)
5.3.2. Subcutaneous
5.3.2.1. Subcutaneous Bispecific Antibody Therapeutics Contract Manufacturing Market, 2018 to 2030 (USD Million)
5.3.3. Others
5.3.3.1. Others Bispecific Antibody Therapeutics Contract Manufacturing Market, 2018 to 2030 (USD Million)
Chapter 6. Bispecific Antibody Therapeutics Contract Manufacturing Market: End-use Estimates & Trend Analysis
6.1. Bispecific Antibody Therapeutics Contract Manufacturing Market, By End-use: Segment Dashboard
6.2. Bispecific Antibody Therapeutics Contract Manufacturing Market, By End-use: Movement Analysis
6.3. Bispecific Antibody Therapeutics Contract Manufacturing Market Estimates & Forecasts, By End-use, 2018 - 2030
6.3.1. Pharmaceutical Companies
6.3.1.1. Pharmaceutical Companies Bispecific Antibody Therapeutics Contract Manufacturing Market 2018 to 2030 (USD Million)
6.3.2. Biopharmaceutical Companies
6.3.2.1. Biopharmaceutical Companies Bispecific Antibody Therapeutics Contract Manufacturing Market 2018 to 2030 (USD Million)
6.3.3. Others
6.3.3.1. Others Bispecific Antibody Therapeutics Contract Manufacturing Market 2018 to 2030 (USD Million)
Chapter 7. Bispecific Antibody Therapeutics Contract Manufacturing Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2022 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. North America
7.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. U.S. Market Estimates and Forecasts, 2018 - 2030
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Canada Market Estimates and Forecasts, 2018 - 2030
7.5. Europe
7.5.1. UK
7.5.1.1. Key Country Dynamics
7.5.1.2. Competitive Scenario
7.5.1.3. UK Market Estimates and Forecasts, 2018 - 2030
7.5.2. Germany
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Germany Market Estimates and Forecasts, 2018 - 2030
7.5.3. Rest of Europe
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Rest of Europe Market Estimates and Forecasts, 2018 - 2030
7.6. Asia Pacific
7.6.1. Japan
7.6.1.1. Key Country Dynamics
7.6.1.2. Competitive Scenario
7.6.1.3. Japan Market Estimates and Forecasts, 2018 - 2030
7.6.2. China
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. China Market Estimates and Forecasts, 2018 - 2030
7.6.3. Rest of Asia Pacific
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Rest of Asia Pacific Market Estimates and Forecasts, 2018 - 2030
7.7. Rest of Rest of the World
Chapter 8. Competitive Landscape
8.1. Market Participant Categorization
8.1.1. Innovators
8.1.2. Market Leaders
8.1.3. Emerging Players
8.1.4. Company Market Share Analysis, 2022
8.2. Company Profiles
8.3. Company Profiles
8.3.1. Lonza
8.3.1.1. Company Overview
8.3.1.2. Financial Performance
8.3.1.3. Service Benchmarking
8.3.1.4. Strategic Initiatives
8.3.2. Roche's
8.3.2.1. Company Overview
8.3.2.2. Financial Performance
8.3.2.3. Service Benchmarking
8.3.2.4. Strategic Initiatives
8.3.3. Creative Biolabs
8.3.3.1. Company Overview
8.3.3.2. Financial Performance
8.3.3.3. Service Benchmarking
8.3.3.4. Strategic Initiatives
8.3.4. AbbVie
8.3.4.1. Company Overview
8.3.4.2. Financial Performance
8.3.4.3. Service Benchmarking
8.3.4.4. Strategic Initiatives
8.3.5. Amgen
8.3.5.1. Company Overview
8.3.5.2. Financial Performance
8.3.5.3. Service Benchmarking
8.3.5.4. Strategic Initiatives
8.3.6. Janssen
8.3.6.1. Company Overview
8.3.6.2. Financial Performance
8.3.6.3. Service Benchmarking
8.3.6.4. Strategic Initiatives
8.3.7. Johnson & Johnson
8.3.7.1. Company Overview
8.3.7.2. Financial Performance
8.3.7.3. Service Benchmarking
8.3.7.4. Strategic Initiatives
8.3.8. IQVIA
8.3.8.1. Company Overview
8.3.8.2. Financial Performance
8.3.8.3. Service Benchmarking
8.3.8.4. Strategic Initiatives
8.3.9. WuXi Biologics
8.3.9.1. Company Overview
8.3.9.2. Financial Performance
8.3.9.3. Service Benchmarking
8.3.9.4. Strategic Initiatives
8.3.10. Sino Biological Inc
8.3.10.1. Company Overview
8.3.10.2. Financial Performance
8.3.10.3. Service Benchmarking
8.3.10.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of Abbreviations
Table 3 North America Bispecific Antibody Therapeutics Contract Manufacturing Market, by region, 2018 - 2030 (USD Million)
Table 4 North America Bispecific Antibody Therapeutics Contract Manufacturing Market, by Route of Administration Type, 2018 - 2030 (USD Million)
Table 5 North America Bispecific Antibody Therapeutics Contract Manufacturing Market, by Indication, 2018 - 2030 (USD Million)
Table 6 North America Bispecific Antibody Therapeutics Contract Manufacturing Market, by End Use, 2018 - 2030 (USD Million)
Table 7 U.S. Bispecific Antibody Therapeutics Contract Manufacturing Market, by Route of Administration Type, 2018 - 2030 (USD Million)
Table 8 U.S. Bispecific Antibody Therapeutics Contract Manufacturing Market, by Indication, 2018 - 2030 (USD Million)
Table 9 U.S. Bispecific Antibody Therapeutics Contract Manufacturing Market, by End Use, 2018 - 2030 (USD Million)
Table 10 Canada Bispecific Antibody Therapeutics Contract Manufacturing Market, by Route of Administration Type, 2018 - 2030 (USD Million)
Table 11 Canada Bispecific Antibody Therapeutics Contract Manufacturing Market, by Indication, 2018 - 2030 (USD Million)
Table 12 Canada Bispecific Antibody Therapeutics Contract Manufacturing Market, by End Use, 2018 - 2030 (USD Million)
Table 13 Europe Bispecific Antibody Therapeutics Contract Manufacturing Market, by region, 2018 - 2030 (USD Million)
Table 14 Europe Bispecific Antibody Therapeutics Contract Manufacturing Market, by Route of Administration Type, 2018 - 2030 (USD Million)
Table 15 Europe Bispecific Antibody Therapeutics Contract Manufacturing Market, by Indication, 2018 - 2030 (USD Million)
Table 16 Europe Bispecific Antibody Therapeutics Contract Manufacturing Market, by End Use, 2018 - 2030 (USD Million)
Table 17 UK Bispecific Antibody Therapeutics Contract Manufacturing Market, by Route of Administration Type, 2018 - 2030 (USD Million)
Table 18 UK Bispecific Antibody Therapeutics Contract Manufacturing Market, by Indication, 2018 - 2030 (USD Million)
Table 19 UK Bispecific Antibody Therapeutics Contract Manufacturing Market, by End Use, 2018 - 2030 (USD Million)
Table 20 Germany Bispecific Antibody Therapeutics Contract Manufacturing Market, by Route of Administration Type, 2018 - 2030 (USD Million)
Table 21 Germany Bispecific Antibody Therapeutics Contract Manufacturing Market, by Indication, 2018 - 2030 (USD Million)
Table 22 Germany Bispecific Antibody Therapeutics Contract Manufacturing Market, by End Use, 2018 - 2030 (USD Million)
Table 23 Rest of Europe Bispecific Antibody Therapeutics Contract Manufacturing Market, by Route of Administration Type, 2018 - 2030 (USD Million)
Table 24 Rest of Europe Bispecific Antibody Therapeutics Contract Manufacturing Market, by Indication, 2018 - 2030 (USD Million)
Table 25 Rest of Europe Bispecific Antibody Therapeutics Contract Manufacturing Market, by End Use, 2018 - 2030 (USD Million)
Table 26 Asia Pacific Bispecific Antibody Therapeutics Contract Manufacturing Market, by region, 2018 - 2030 (USD Million)
Table 27 Asia Pacific Bispecific Antibody Therapeutics Contract Manufacturing Market, by Route of Administration Type, 2018 - 2030 (USD Million)
Table 28 Asia Pacific Bispecific Antibody Therapeutics Contract Manufacturing Market, by Indication, 2018 - 2030 (USD Million)
Table 29 Asia Pacific Bispecific Antibody Therapeutics Contract Manufacturing Market, by End Use, 2018 - 2030 (USD Million)
Table 30 Japan Bispecific Antibody Therapeutics Contract Manufacturing Market, by Route of Administration Type, 2018 - 2030 (USD Million)
Table 31 Japan Bispecific Antibody Therapeutics Contract Manufacturing Market, by Indication, 2018 - 2030 (USD Million)
Table 32 Japan Bispecific Antibody Therapeutics Contract Manufacturing Market, by End Use, 2018 - 2030 (USD Million)
Table 33 China Bispecific Antibody Therapeutics Contract Manufacturing Market, by Route of Administration Type, 2018 - 2030 (USD Million)
Table 34 China Bispecific Antibody Therapeutics Contract Manufacturing Market, by Indication, 2018 - 2030 (USD Million)
Table 35 China Bispecific Antibody Therapeutics Contract Manufacturing Market, by End Use, 2018 - 2030 (USD Million)
Table 36 Rest of Asia Pacific Bispecific Antibody Therapeutics Contract Manufacturing Market, by Route of Administration Type, 2018 - 2030 (USD Million)
Table 37 Rest of Asia Pacific Bispecific Antibody Therapeutics Contract Manufacturing Market, by Indication, 2018 - 2030 (USD Million)
Table 38 Rest of Asia Pacific Bispecific Antibody Therapeutics Contract Manufacturing Market, by End Use, 2018 - 2030 (USD Million)
Table 39 Rest of Rest of the World Bispecific Antibody Therapeutics Contract Manufacturing Market, by region, 2018 - 2030 (USD Million)
Table 40 Rest of Rest of the World Bispecific Antibody Therapeutics Contract Manufacturing Market, by Route of Administration Type, 2018 - 2030 (USD Million)
Table 41 Rest of Rest of the World Bispecific Antibody Therapeutics Contract Manufacturing Market, by Indication, 2018 - 2030 (USD Million)
Table 42 Rest of Rest of the World Bispecific Antibody Therapeutics Contract Manufacturing Market, by End Use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Market research approaches
Fig. 4 QFD modeling for market share assessment
Fig. 5 Market formulation & validation
Fig. 6 Commodity flow analysis
Fig. 7 Primary research pattern
Fig. 8 Primary interviews in North America
Fig. 9 Primary interviews in Europe
Fig. 10 Primary interviews in the Asia Pacific
Fig. 11 Primary interviews in Latin America
Fig. 12 Primary interviews in MEA
Fig. 13 Market Snapshot
Fig. 14 Segment Snapshot
Fig. 15 Segment Snapshot
Fig. 16 Competitive Landscape Snapshot
Fig. 17 Bispecific Antibody Therapeutics Contract Manufacturing Market segmentation
Fig. 18 Parent market outlook (2022)
Fig. 19 Related/ancillary market outlook (2022)
Fig. 20 Market driver relevance analysis (Current & future impact)
Fig. 21 Current shared services and outsourcing usage levels
Fig. 22 Market restraint relevance analysis (Current & future impact)
Fig. 23 Porter’s five forces analysis
Fig. 24 SWOT analysis, by a factor (political & legal, economic and technological)
Fig. 25 Bispecific Antibody Therapeutics Contract Manufacturing Market Indication outlook: Segment dashboard
Fig. 26 Bispecific Antibody Therapeutics Contract Manufacturing:Indication movement analysis
Fig. 27 Cancer market, 2018 - 2030 (USD Million)
Fig. 28 Infectious Diseases market, 2018 - 2030 (USD Million)
Fig. 29 Autoinflammatory and autoimmune diseases market, 2018 - 2030 (USD Million)
Fig. 30 CNS Conditions market, 2018 - 2030 (USD Million)
Fig. 31 Others market, 2018 - 2030 (USD Million)
Fig. 32 Bispecific Antibody Therapeutics Contract Manufacturing Market Route of Administration type outlook: Segment dashboard
Fig. 33 Bispecific Antibody Therapeutics Contract Manufacturing: Route of Administrationtype movement analysis
Fig. 34 Intravenous market, 2018 - 2030 (USD Million)
Fig. 35 Subcutaneous market, 2018 - 2030 (USD Million)
Fig. 36 Others market, 2018 - 2030 (USD Million)
Fig. 37 Bispecific Antibody Therapeutics Contract Manufacturing Market End Use outlook: Segment dashboard
Fig. 38 Bispecific Antibody Therapeutics Contract Manufacturing Market: End Use movement analysis
Fig. 39 Pharmaceutical Companies market, 2018 - 2030 (USD Million)
Fig. 40 Biopharmaceutical Companies market, 2018 - 2030 (USD Million)
Fig. 41 Others market, 2018 - 2030 (USD Million)
Fig. 42 Regional marketplace: Segment dashboard
Fig. 43 Regional outlook, 2022 & 2030
Fig. 44 North America market, 2018 - 2030 (USD Million)
Fig. 45 U.S. market, 2018 - 2030 (USD Million)
Fig. 46 Canada market, 2018 - 2030 (USD Million)
Fig. 47 Europe market, 2018 - 2030 (USD Million)
Fig. 48 UK market, 2018 - 2030 (USD Million)
Fig. 49 Germany market, 2018 - 2030 (USD Million)
Fig. 50 Rest of Europe market, 2018 - 2030 (USD Million)
Fig. 51 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 52 China market, 2018 - 2030 (USD Million)
Fig. 53 Japan market, 2018 - 2030 (USD Million)
Fig. 54 Rest of Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 55 Rest of Rest of the World market, 2018 - 2030 (USD Million)

Companies Mentioned

  • Lonza
  • Roche's
  • Creative Biolabs
  • AbbVie
  • Amgen
  • Janssen
  • Johnson & Johnson
  • IQVIA
  • WuXi Biologics
  • Sino Biological Inc

Methodology

Loading
LOADING...

Table Information